| __timestamp | BioCryst Pharmaceuticals, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 91733000 |
| Thursday, January 1, 2015 | 13047000 | 87644000 |
| Friday, January 1, 2016 | 11253000 | 92365000 |
| Sunday, January 1, 2017 | 13933000 | 85656000 |
| Monday, January 1, 2018 | 29514000 | 88196000 |
| Tuesday, January 1, 2019 | 37121000 | 89971000 |
| Wednesday, January 1, 2020 | 67929000 | 93413000 |
| Friday, January 1, 2021 | 118818000 | 91355000 |
| Saturday, January 1, 2022 | 159371000 | 113676000 |
| Sunday, January 1, 2023 | 213894000 | 198366000 |
| Monday, January 1, 2024 | 218935000 |
Data in motion
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Taro Pharmaceutical Industries Ltd. and BioCryst Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenses over the past decade. From 2014 to 2023, Taro maintained a relatively stable SG&A cost, averaging around $113 million annually, with a notable peak in 2023. In contrast, BioCryst's SG&A expenses surged by nearly 280% from 2014 to 2023, reflecting their aggressive expansion strategy. While Taro's consistent cost management suggests a focus on operational efficiency, BioCryst's rising expenses indicate a potential investment in growth and innovation. As of 2023, Taro's SG&A expenses were approximately 7% lower than BioCryst's, highlighting their effective cost control. However, the absence of BioCryst's 2024 data leaves room for speculation on their future financial strategy.
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
ACADIA Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Supernus Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.